GPATCH8

Summary

GPATCH8 (G-patch domain containing 8, HGNC:29066) is a protein-coding gene on chromosome 17q21.31, encoding G patch domain-containing protein 8 (Q9UKJ3).

The protein encoded by this gene contains an RNA-processing domain, a zinc finger domain, a lysine-rich region and a serine-rich region. A mutation in the serine-rich region of the protein is thought to be associated with hyperuricemia (PMID: 21594610). Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 23131 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 202 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001002909

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29066
Approved symbol	GPATCH8
Name	G-patch domain containing 8
Location	17q21.31
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000186566
Ensembl biotype	protein_coding
OMIM	614396
Entrez	23131

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 5 protein_coding, 4 retained_intron, 4 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000335500, ENST00000585614, ENST00000586037, ENST00000586265, ENST00000587228, ENST00000588554, ENST00000590041, ENST00000591680, ENST00000592154, ENST00000592746, ENST00000635257, ENST00000928548, ENST00000928549, ENST00000928550

RefSeq mRNA: 6 — MANE Select: NM_001002909 NM_001002909, NM_001304939, NM_001304940, NM_001304941, NM_001304942, NM_001304943

CCDS: CCDS32666

Canonical transcript exons

ENST00000591680 — 8 exons

Exon	Start	End
ENSE00003477376	44395281	44401453
ENSE00003520559	44464472	44464544
ENSE00003535829	44424349	44424492
ENSE00003599247	44474829	44474903
ENSE00003606039	44503326	44503406
ENSE00003627203	44436478	44436545
ENSE00003644528	44405921	44406051
ENSE00003677877	44435065	44435151

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 96.18.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.6575 / max 251.8593, expressed in 1808 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
166382	11.6549	1771
166385	6.0120	1583
166384	1.7096	811
166383	0.2810	115

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	96.18	gold quality
secondary oocyte	CL:0000655	95.45	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.88	gold quality
cerebellar hemisphere	UBERON:0002245	94.80	gold quality
cerebellar cortex	UBERON:0002129	94.68	gold quality
cerebellum	UBERON:0002037	93.98	gold quality
olfactory bulb	UBERON:0002264	93.32	gold quality
gastrocnemius	UBERON:0001388	93.16	gold quality
calcaneal tendon	UBERON:0003701	93.06	gold quality
nipple	UBERON:0002030	92.98	gold quality
muscle of leg	UBERON:0001383	92.97	gold quality
colonic epithelium	UBERON:0000397	92.89	gold quality
lateral globus pallidus	UBERON:0002476	92.51	gold quality
pylorus	UBERON:0001166	92.39	gold quality
inferior olivary complex	UBERON:0002127	92.36	gold quality
cardia of stomach	UBERON:0001162	91.89	gold quality
tendon of biceps brachii	UBERON:0008188	91.83	gold quality
tendon	UBERON:0000043	91.56	gold quality
Brodmann (1909) area 23	UBERON:0013554	91.29	gold quality
type B pancreatic cell	CL:0000169	91.28	gold quality
muscle organ	UBERON:0001630	91.19	gold quality
inferior vagus X ganglion	UBERON:0005363	90.99	gold quality
ventricular zone	UBERON:0003053	90.90	gold quality
visceral pleura	UBERON:0002401	90.68	gold quality
hindlimb stylopod muscle	UBERON:0004252	90.64	gold quality
primary visual cortex	UBERON:0002436	90.56	gold quality
lateral nuclear group of thalamus	UBERON:0002736	90.51	gold quality
substantia nigra pars reticulata	UBERON:0001966	90.45	gold quality
corpus callosum	UBERON:0002336	90.44	gold quality
tibialis anterior	UBERON:0001385	90.40	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.83
E-CURD-135	no	695.46

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

200 targeting GPATCH8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-570-3P	99.96	72.41	4910

Literature-anchored findings (GeneRIF, showing 2)

• Two missense single-nucleotide variants in ZPBP2 and GPATCH8 on chromosome 17 were identified that cosegregated with hyperuricemia in the Japanese family. (PMID:21594610)
• GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies. (PMID:38688280)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	gpatch8	ENSDARG00000059768
mus_musculus	Gpatch8	ENSMUSG00000034621
rattus_norvegicus	Gpatch8	ENSRNOG00000021044

Paralogs (2): ZNF804A (ENSG00000170396), ZNF804B (ENSG00000182348)

Protein

Protein identifiers

G patch domain-containing protein 8 — Q9UKJ3 (reviewed: Q9UKJ3)

All UniProt accessions (3): K7EKU0, K7EQK8, Q9UKJ3

UniProt curated annotations — full annotation on UniProt →

Isoforms (3)

UniProt ID	Names	Canonical?
Q9UKJ3-1	1	yes
Q9UKJ3-2	2
Q9UKJ3-3	3

RefSeq proteins (5): NP_001002909, NP_001291868, NP_001291869, NP_001291870, NP_001291871 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000467	G_patch_dom	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR052445	ZNF804A-like/GPATCH8	Family

Pfam: PF01585

UniProt features (60 total): compositionally biased region 21, modified residue 16, sequence variant 5, region of interest 4, sequence conflict 4, cross-link 3, splice variant 3, chain 1, domain 1, zinc finger region 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UKJ3-F1	46.49	0.05

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (19): 479, 491, 653, 738, 740, 758, 911, 914, 981, 1009, 1014, 1033, 1035, 1081, 1107, 1175, 311, 577, 1105

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 163 (showing top): MORF_FLT1, MORF_MSH3, DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_DN, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, TTTGTAG_MIR520D, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, MORF_BRCA1, MORF_ATRX, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, MORF_ESR1, TTGGGAG_MIR150, GTGCCTT_MIR506, DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_DN, GOBP_RNA_SPLICING, GGCAGTG_MIR3243P

GO Biological Process (2): mRNA splicing, via spliceosome (GO:0000398), hemopoiesis (GO:0030097)

GO Molecular Function (6): RNA binding (GO:0003723), mRNA binding (GO:0003729), zinc ion binding (GO:0008270), nucleic acid binding (GO:0003676), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
cell development	1
nucleic acid binding	1
RNA binding	1
transition metal ion binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

980 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPATCH8	DDA1	Q9BW61	475
GPATCH8	PCDHB13	Q9Y5F0	390
GPATCH8	WDR6	Q9NNW5	371
GPATCH8	UBE4B	O95155	368
GPATCH8	RUNDC1	Q96C34	354
GPATCH8	PYM1	Q9BRP8	354
GPATCH8	GPRIN1	Q7Z2K8	342
GPATCH8	NT5C3B	Q969T7	341
GPATCH8	GARRE1	O15063	326
GPATCH8	ZNF778	Q96MU6	324
GPATCH8	CCDC43	Q96MW1	322
GPATCH8	ADPRHL1	Q8NDY3	321
GPATCH8	SCNM1	Q9BWG6	320
GPATCH8	TMEM101	Q96IK0	317
GPATCH8	BLTP1	Q2LD37	315

IntAct

107 interactions, top by confidence:

A	B	Type	Score
SNRPF	GEMIN2	psi-mi:“MI:0914”(association)	0.910
SNRPE	GEMIN2	psi-mi:“MI:0914”(association)	0.770
CAMKV	AP3B1	psi-mi:“MI:0914”(association)	0.640
SNRPA1	U2SURP	psi-mi:“MI:0914”(association)	0.640
SNRPB	SART1	psi-mi:“MI:0914”(association)	0.640
PIP4K2A	AP3B1	psi-mi:“MI:0914”(association)	0.530
EPB41L2	AP3B1	psi-mi:“MI:0914”(association)	0.530
SNIP1	CASC3	psi-mi:“MI:0914”(association)	0.530
LACC1	DUSP14	psi-mi:“MI:0914”(association)	0.530
JPH4	ZSWIM8	psi-mi:“MI:0914”(association)	0.530
EPB41L1	AP3B1	psi-mi:“MI:0914”(association)	0.530
EPB41L3	AP3B1	psi-mi:“MI:0914”(association)	0.530
LUC7L2	CASC3	psi-mi:“MI:0914”(association)	0.530
SRPK2	RRP9	psi-mi:“MI:0914”(association)	0.530
SNRPC	SNRPGP15	psi-mi:“MI:0914”(association)	0.530
U2AF2	U2SURP	psi-mi:“MI:0914”(association)	0.480
H1-5	GPATCH8	psi-mi:“MI:0915”(physical association)	0.400
GPATCH8	H2BC9	psi-mi:“MI:0915”(physical association)	0.400
H2AX	GPATCH8	psi-mi:“MI:0915”(physical association)	0.400
GPATCH8	HIST2H2BF	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (147): GPATCH8 (Affinity Capture-MS), GPATCH8 (Affinity Capture-MS), GPATCH8 (Affinity Capture-MS), GPATCH8 (Affinity Capture-MS), GPATCH8 (Affinity Capture-MS), GPATCH8 (Affinity Capture-MS), GPATCH8 (Affinity Capture-MS), GPATCH8 (Affinity Capture-MS), GPATCH8 (Affinity Capture-MS), GPATCH8 (Affinity Capture-MS), GPATCH8 (Two-hybrid), GPATCH8 (Proximity Label-MS), ABCA2 (Affinity Capture-MS), FDX1 (Affinity Capture-MS), PON2 (Affinity Capture-MS)

ESM2 similar proteins: A2A6A1, B0BN49, B0QZF7, D2H526, E1BB50, E9PYH6, E9Q4F7, E9Q6J5, F1Q8W0, O15047, O88453, P30414, P30415, Q01538, Q14AX6, Q17QQ9, Q27450, Q3KPW4, Q3UMU9, Q4V8I5, Q505I5, Q5BKY9, Q5SW79, Q5VZP5, Q62417, Q66648, Q66PJ3, Q6A065, Q6P9P0, Q6UB99, Q7TQC7, Q7Z4V5, Q80U49, Q86VM9, Q8BYK8, Q8C5W0, Q8CFC2, Q8NEY8, Q8R0F5, Q8R2M2

Diamond homologs: A2A6A1, A2AKY4, B2GV05, P52756, Q1RMU5, Q6DF57, Q6DGZ0, Q7Z570, Q91YE7, Q94C11, Q9UKJ3, A4D1E1, A0JMV4, A4IGK4, P70501, P87143, P98175, Q0IIX9, Q4PC17, Q66J74, Q6C233, Q6DDU9, Q7TN31, Q7TQC7, Q8CH09, Q8N302, Q99KG3, Q9NW75, A6ZRL6, A8XYX2, A8XYX3, C6Y4A5, P53866, Q17784, Q2KI19, Q3UFS4, Q875B6, Q8IX01, Q8N954, Q9NAA5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 106 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transport of Mature Transcript to Cytoplasm	7	37.0×	2e-08
RNA Polymerase II Transcription Termination	10	30.5×	3e-11
mRNA Splicing	18	27.4×	2e-19
mRNA 3’-end processing	8	21.9×	9e-08
mRNA Splicing - Minor Pathway	7	21.8×	8e-07
Processing of Capped Intron-Containing Pre-mRNA	19	21.7×	9e-19
mRNA Polyadenylation	16	19.5×	5e-15
mRNA Splicing - Major Pathway	24	18.2×	7e-22

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of mRNA splicing, via spliceosome	6	47.9×	2e-07
spliceosomal snRNP assembly	7	42.4×	4e-08
U2-type prespliceosome assembly	6	39.0×	8e-07
RNA splicing, via transesterification reactions	5	32.5×	3e-05
spliceosomal complex assembly	5	31.4×	3e-05
regulation of alternative mRNA splicing, via spliceosome	7	17.8×	1e-05
RNA processing	7	16.0×	2e-05
RNA splicing	16	14.7×	7e-12

Disease & clinical

Clinical variants and AI predictions

ClinVar

202 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	186
Likely benign	7
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2490 predictions. Top by Δscore:

Variant	Effect	Δscore
17:44401452:CA:C	acceptor_gain	1.0000
17:44401454:C:CC	acceptor_gain	1.0000
17:44401466:T:C	acceptor_gain	1.0000
17:44401466:T:TC	acceptor_gain	1.0000
17:44405915:CCTCA:C	donor_loss	1.0000
17:44405916:CTCA:C	donor_loss	1.0000
17:44405919:A:AC	donor_gain	1.0000
17:44405919:A:AT	donor_loss	1.0000
17:44405919:AC:A	donor_gain	1.0000
17:44405920:C:CC	donor_gain	1.0000
17:44405920:C:CT	donor_loss	1.0000
17:44405920:CC:C	donor_gain	1.0000
17:44405920:CCATT:C	donor_gain	1.0000
17:44406047:AATCT:A	acceptor_gain	1.0000
17:44406048:ATCT:A	acceptor_gain	1.0000
17:44406050:CT:C	acceptor_gain	1.0000
17:44406052:C:CC	acceptor_gain	1.0000
17:44406056:G:GC	acceptor_gain	1.0000
17:44406057:T:C	acceptor_gain	1.0000
17:44406057:T:TC	acceptor_gain	1.0000
17:44424344:CTCA:C	donor_loss	1.0000
17:44424345:TCA:T	donor_loss	1.0000
17:44424346:CA:C	donor_loss	1.0000
17:44424347:A:C	donor_loss	1.0000
17:44424348:C:CA	donor_loss	1.0000
17:44424348:CCTG:C	donor_gain	1.0000
17:44424488:TAATC:T	acceptor_gain	1.0000
17:44424501:CCCA:C	acceptor_gain	1.0000
17:44424503:C:CT	acceptor_gain	1.0000
17:44424504:A:AC	acceptor_gain	1.0000

AlphaMissense

9855 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:44398097:G:T	A1327D	1.000
17:44398098:C:G	A1327P	1.000
17:44398101:C:G	A1326P	1.000
17:44398109:A:G	L1323P	1.000
17:44398109:A:T	L1323H	1.000
17:44398118:T:C	Y1320C	1.000
17:44398119:A:G	Y1320H	1.000
17:44398141:G:C	F1312L	1.000
17:44398141:G:T	F1312L	1.000
17:44398142:A:C	F1312C	1.000
17:44398142:A:G	F1312S	1.000
17:44398143:A:G	F1312L	1.000
17:44400424:C:A	W551C	1.000
17:44400424:C:G	W551C	1.000
17:44400426:A:G	W551R	1.000
17:44400426:A:T	W551R	1.000
17:44400458:A:T	V540D	1.000
17:44405957:A:G	L196P	1.000
17:44406011:A:T	V178D	1.000
17:44406013:A:C	N177K	1.000
17:44406013:A:T	N177K	1.000
17:44406017:C:G	R176P	1.000
17:44406022:A:C	F174L	1.000
17:44406022:A:T	F174L	1.000
17:44406023:A:C	F174C	1.000
17:44406023:A:G	F174S	1.000
17:44406024:A:G	F174L	1.000
17:44406027:C:T	E173K	1.000
17:44406028:T:A	R172S	1.000
17:44406028:T:G	R172S	1.000

dbSNP variants (sampled 300 via entrez): RS1000007733 (17:44482108 G>A,C), RS1000046764 (17:44456492 A>G), RS1000055704 (17:44499226 G>A,C), RS1000069128 (17:44493505 T>C), RS1000070753 (17:44493721 C>T), RS1000107192 (17:44412652 G>A), RS1000132007 (17:44441726 C>A,T), RS1000159290 (17:44471629 G>A), RS1000160476 (17:44420169 C>G,T), RS1000211150 (17:44476379 T>C), RS1000214675 (17:44419872 A>C), RS1000240885 (17:44469543 T>C), RS1000276168 (17:44450104 G>C), RS1000306524 (17:44469298 C>T), RS1000353803 (17:44422316 C>T)

Disease associations

OMIM: gene MIM:614396 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST007269_163	Pulse pressure	6.000000e-13
GCST010703_292	Brain morphology (MOSTest)	1.000000e-14

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005763	pulse pressure measurement
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523489 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.00	IC50	10	nM	MOLIBRESIB
7.92	Kd	12	nM	MOLIBRESIB

PubChem BioAssay actives

2 with measured affinity, of 8 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178759: Inhibition of GPATCH8 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	0.0100	uM

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	2
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
dicrotophos	increases expression	1
testosterone enanthate	affects expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	decreases expression	1
arsenite	affects binding, decreases reaction	1
ferrous chloride	decreases expression	1
aflatoxin B2	decreases methylation	1
di-n-butylphosphoric acid	affects expression	1
abrine	increases expression	1
bisphenol S	affects cotreatment, increases expression	1
Caffeine	affects phosphorylation	1
Cisplatin	decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Hydrogen Peroxide	affects cotreatment, increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Ribonucleotides	affects binding	1
Dronabinol	increases expression	1
Theophylline	affects cotreatment, increases expression	1
Thiram	increases expression	1
Vitamin E	decreases expression	1
1-Methyl-3-isobutylxanthine	increases expression, affects cotreatment	1
Palmitic Acid	decreases phosphorylation	1
Lactic Acid	decreases expression	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4341442	Binding	Binding affinity to GPATCH8 in human A549 cells lysates grown on SILAC media at 10 uM incubated for 1 hr by LC-MS/MS analysis relative to untreated control	Profiling withanolide A for therapeutic targets in neurodegenerative diseases. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.